Page last updated: 2024-10-25

cimetidine and Mast-Cell Sarcoma

cimetidine has been researched along with Mast-Cell Sarcoma in 1 studies

Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.

Mast-Cell Sarcoma: A unifocal malignant tumor that consists of atypical pathological MAST CELLS without systemic involvement. It causes local destructive growth in organs other than in skin or bone marrow.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Trumel, C1
Bourgès-Abella, N1
Touron, C1
Lanore, D1
Geffré, A1
Diquelou, A1
Guelfi, JF1
Braun, JP1

Other Studies

1 other study available for cimetidine and Mast-Cell Sarcoma

ArticleYear
Adverse haematological effects of vinblastine, prednisolone and cimetidine treatment: a retrospective study in fourteen dogs with mast cell tumours.
    Journal of veterinary medicine. A, Physiology, pathology, clinical medicine, 2005, Volume: 52, Issue:6

    Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic;

2005